Unichem Labs Q1 FY27 Results: Consolidated Profit at ₹41.47 Cr, Revenue at ₹632.62 Cr
Unichem Laboratories reported Q1 FY27 results. Consolidated profit after tax was ₹41.47 crore on revenue of ₹632.62 crore. Standalone profit after tax was ₹5.53 crore on revenue of ₹366.27 crore. The company invested ₹0.76 crore in its China subsidiary. Results approved by the board on August 11, 2026.
The positive financial results, especially the turnaround from loss to profit on both consolidated and standalone bases, are material for investors and could influence stock performance. The investment in a subsidiary also adds to the company's strategic activities.
The company reported a profit after tax for both consolidated and standalone entities in Q1 FY27, a significant improvement from the previous year's losses, indicating positive financial performance.
Unichem Laboratories Limited announced its unaudited financial results for the first quarter ended June 30, 2026. The company's Board of Directors approved the consolidated and standalone financial statements during a meeting held on August 11, 2026. The meeting commenced at 12:00 noon and concluded at 1:45 p.m.
On a consolidated basis, Unichem Laboratories reported a total income of ₹648.23 crore for the quarter, an increase from ₹533.42 crore in the corresponding quarter of the previous year. Profit after tax for the quarter stood at ₹41.47 crore, a significant improvement from a loss of ₹10.47 crore in Q1 FY26. Revenue from operations for the consolidated entity was ₹632.62 crore.
The standalone results for the quarter ended June 30, 2026, showed a total income of ₹382.99 crore. Profit after tax for the standalone entity was ₹5.53 crore, compared to a loss of ₹1.85 crore in the same period last year. Revenue from operations on a standalone basis was ₹366.27 crore. The company also reported an investment of USD 80,000 (approximately ₹0.76 crore) towards redeemable preference shares in its wholly-owned subsidiary, Unichem (China) Pvt Ltd.
The financial statements were reviewed by the Audit Committee and approved by the Board. The statutory auditors have provided an unmodified conclusion on these results. The results will be available on the company's website and the BSE and NSE websites.
What to do with a filing like this
Unichem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Unichem Laboratories Limited. Read the original for the full detail.